We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.26B
AUM Growth
-$664M
Cap. Flow
-$732M
Cap. Flow %
-58.11%
Top 10 Hldgs %
59.75%
Holding
95
New
14
Increased
22
Reduced
15
Closed
35

Top Buys

Rank Stock Value
1
BIOA
BioAge Labs
BIOA
+$46.2M
2
INCY icon
Incyte
INCY
+$45.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$22.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$20.7M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$13.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$100M
2
SYK icon
Stryker
SYK
+$65.7M
3
ALGN icon
Align Technology
ALGN
+$52.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$38.8M
5
EW icon
Edwards Lifesciences
EW
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.63M
$1.78M 0.14%
137,722
– –
GPCR icon
52
Structure Therapeutics
GPCR
$3.46B
$1.7M 0.14%
38,792
+29,877
+335% +$1.16M
CATX icon
53
Perspective Therapeutics
CATX
$322M
$1.61M 0.13%
120,632
-11,457
-9% -$152K
RNAM
54
DELISTED
Avidity Biosciences
RNAM
$1.4M 0.11%
30,472
+9,047
+42% +$393K
VIR icon
55
Vir Biotechnology
VIR
$1.48B
$968K 0.08%
+129,246
New +$1.12M
ATXS
56
DELISTED
Astria Therapeutics
ATXS
$943K 0.07%
85,640
+24,948
+41% +$277K
IMTXW
57
DELISTED
Immatics N.V. Warrants
IMTXW
$852K 0.07%
366,568
+17,837
+5% +$49.9K
IMA
58
ImageneBio Inc
IMA
$63.2M
$662K 0.05%
31,885
– –
REPL icon
59
Replimune Group
REPL
$724M
$528K 0.04%
+48,138
New +$489K
LUNG icon
60
Pulmonx
LUNG
$51.5M
$517K 0.04%
62,313
+2,067
+3% +$15K
ABT icon
61
CALL
Abbott
ABT
$182B
– –
-390,200
Closed -$40.5M
ALGN icon
62
Align Technology
ALGN
$12B
– –
-218,524
Closed -$52.8M
ALNY icon
63
CALL
Alnylam Pharmaceuticals
ALNY
$37.2B
– –
-50,000
Closed -$12.2M
ALNY icon
64
Alnylam Pharmaceuticals
ALNY
$37.2B
– –
-147,929
Closed -$35.9M
AMLX icon
65
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-299,691
Closed -$569K
AMLX icon
66
PUT
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-300,000
Closed -$570K
ASND icon
67
Ascendis Pharma A/S
ASND
$16.6B
– –
-734,284
Closed -$100M
AVTR icon
68
Avantor
AVTR
$8.03B
– –
-141,045
Closed -$2.99M
BAX icon
69
Baxter International
BAX
$12.1B
– –
-117,769
Closed -$3.94M
CLDX icon
70
Celldex Therapeutics
CLDX
$2.8B
– –
-547,707
Closed -$20.3M
DXCM icon
71
DexCom
DXCM
$28.3B
– –
-61,494
Closed -$6.97M
EW icon
72
PUT
Edwards Lifesciences
EW
$47.8B
– –
-500,000
Closed -$46.2M
FDMT icon
73
4D Molecular Therapeutics
FDMT
$543M
– –
-271,155
Closed -$5.69M
IDXX icon
74
Idexx Laboratories
IDXX
$43.9B
– –
-63,862
Closed -$31.1M
INSP icon
75
Inspire Medical Systems
INSP
$1.47B
– –
-10,000
Closed -$1.34M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2024 Portfolio in Review

As of Q3 2024, Sofinnova Investments held 95 positions worth $1.26B, down 35% from $1.92B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments withdrew a net $732M in Q3 2024, closing 35 positions and reducing 15 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $100M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 82% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in BioAge Labs worth $47.9M.

  • Sofinnova Investments's largest Q3 2024 buy was BioAge Labs: 2,304,901 shares worth $47.9M.
  • Sofinnova Investments added most to IDEAYA Biosciences in Q3 2024, an estimated $22.7M increase.
  • Sofinnova Investments's biggest Q3 2024 reduction was Edwards Lifesciences, cutting an estimated $37.9M.
  • Sofinnova Investments fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $100M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.26B portfolio in Q3 2024.
  • Sofinnova Investments opened 14 new positions and closed 35 in Q3 2024.
  • Sofinnova Investments's portfolio value fell 35% quarter-over-quarter to $1.26B.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.